Combined oral cyclophosphamide and bevacizumab in heavily pre-treated ovarian cancer.
BACKGROUND
Metronomic chemotherapy combined with bevacizumab has proved to be effective in various tumour types. The aim of this study is to review our experience in recurrent ovarian carcinomas treated with low-dose cyclophosphamide and bevacizumab.


METHODS
Retrospective analysis of pre-treated ovarian cancer patients, i.e., > or =2 previous chemotherapy regimens who received treatment with oral cyclophosphamide 50 mg/day and bevacizumab 10 mg/kg IV every two weeks. Patients with a performance status 0-2 were included. The endpoints were response rates, progressionfree disease and safety profile.


RESULTS
Nine patients with advanced, measurable ovarian cancer were included. Of these, 8 were platinum-resistant and had received prior regimens with gemcitabine (88%), topotecan (77%) and liposomal doxorubicin (66%). There was a mean of 5 previous lines of chemotherapy, range 2-7. Applying RECIST criteria, the efficacy data were as follows: objective response (OR) 44%; 4/9 (CR 2/9 and PR 2/9), SD 2/9 and DP 3/9. At 6 months, 33% of patients were progression free. Response lasted for 12.5 months in three patients treated for 12 months; a further two patients who were re-treated achieved complete response. Mean time to progression was 5.5 months (95% CI 4.5-5.5). No severe adverse effects were reported. Only one patient had to delay several cycles due to G3 haematuria. Other toxicities observed include G3 abdominal pain (1 case); G2 mucositis and G2 dyspnoea in one patient.


CONCLUSIONS
Combined bevacizumab and metronomic oral cyclophosphamide is a safe and effective regimen for heavily pre-treated ovarian cancer patients. Further research is needed on predictive factors to screen for those patients who will benefit from anti-angiogenic therapy.
Jurado
José Miguel
JM
Medical Oncology Service, Hospital Universitario Virgen de la Victoria, Málaga, Spain. josemi88@hotmail.com
Jurado García
José Miguel
JM
Sánchez
Alfonso
A
Pajares
Bella
B
Pérez
Elisabeth
E
Alonso
Lorenzo
L
Alba
Emilio
E
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab; D003520:Cyclophosphamide / Q000008:administration & dosage; D018284:Cystadenocarcinoma, Serous / Q000188:drug therapy* / Q000556:secondary; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis / Q000188:drug therapy*; D009944:Organoplatinum Compounds / Q000009:adverse effects; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology; D012189:Retrospective Studies; D016879:Salvage Therapy; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D009944:Organoplatinum Compounds; D000068258:Bevacizumab; D003520:Cyclophosphamide
J Clin Oncol. 2001 Oct 15;19(20):4054-7
11600607
J Clin Oncol. 2008 Jan 1;26(1):76-82
18165643
N Engl J Med. 2004 Jun 3;350(23):2335-42
15175435
Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6966-71
16203789
Cancer Lett. 1997 Dec 23;121(2):169-75
9570355
Gynecol Oncol. 1999 Feb;72(2):148-53
10021293
Bioessays. 1991 Jan;13(1):31-6
1722975
J Clin Oncol. 2003 May 15;21(10 Suppl):187s-193s
12743133
J Clin Oncol. 2007 Nov 20;25(33):5165-71
18024863
Cancer Res. 2001 Oct 15;61(20):7501-6
11606386
Eur J Cancer. 2000 Jun;36(10):1248-57
10882863
J Clin Oncol. 2003 Sep 1;21(17):3194-200
12860964
Biochem Biophys Res Commun. 2005 Jul 29;333(2):328-35
15961063
J Clin Oncol. 2007 Jul 10;25(20):2902-8
17617521
Cancer Res. 2002 May 15;62(10):2731-5
12019144
Cancer. 2006 Jul 1;107(1):83-9
16736514
Trends Cell Biol. 2001 Nov;11(11):S32-6
11684440
J Clin Oncol. 2001 Jul 15;19(14):3312-22
11454878
J Clin Oncol. 2002 May 1;20(9):2365-9
11981009
Br J Cancer. 2000 Jul;83(2):196-203
10901370
J Clin Oncol. 2007 Nov 20;25(33):5180-6
18024865
J Clin Oncol. 2002 Nov 1;20(21):4368-80
12409337
Cell. 2000 Jan 7;100(1):57-70
10647931
J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
10655437
CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66
17237035
Semin Oncol. 2001 Apr;28(2 Suppl 7):18-24
11372048
Br J Cancer. 1997;76(9):1221-7
9365173